Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Cash from Operations (2021 - 2025)

Coeptis Therapeutics Holdings has reported Cash from Operations over the past 5 years, most recently at 1687910.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 1687910.0 for Q4 2025, down 17.5% from a year ago — trailing twelve months through Dec 2025 was 8603036.0 (down 29.38% YoY), and the annual figure for FY2025 was 8603036.0, down 29.38%.
  • Cash from Operations for Q4 2025 was 1687910.0 at Coeptis Therapeutics Holdings, up from 2152217.0 in the prior quarter.
  • Over the last five years, Cash from Operations for COEPW hit a ceiling of 59847.0 in Q3 2021 and a floor of 4166890.0 in Q4 2021.
  • Median Cash from Operations over the past 5 years was 1686190.0 (2023), compared with a mean of 1542854.1.
  • Peak annual rise in Cash from Operations hit 79.66% in 2022, while the deepest fall reached 1626.42% in 2022.
  • Coeptis Therapeutics Holdings' Cash from Operations stood at 4166890.0 in 2021, then skyrocketed by 79.66% to 847352.0 in 2022, then crashed by 99.89% to 1693786.0 in 2023, then increased by 15.19% to 1436538.0 in 2024, then fell by 17.5% to 1687910.0 in 2025.
  • The last three reported values for Cash from Operations were 1687910.0 (Q4 2025), 2152217.0 (Q3 2025), and 2396742.0 (Q2 2025) per Business Quant data.